Literature DB >> 11254552

Leukotriene B4 augments neutrophil phagocytosis of Klebsiella pneumoniae.

P Mancuso1, P Nana-Sinkam, M Peters-Golden.   

Abstract

Neutrophils play a critical role in the clearance of bacteria from the lung and other organs by their capacity for phagocytosis and killing. Previously, we identified an important role for the leukotrienes in rat alveolar macrophage phagocytosis of Klebsiella pneumoniae. In this report, we explored the possibility that the leukotrienes play an important role in phagocytosis by neutrophils as well. Inhibition of endogenous leukotriene synthesis by 5-lipoxygenase knockout in mice or by pharmacologic means in human peripheral blood neutrophils attenuated phagocytosis of opsonized K. pneumoniae. Reduced phagocytosis was also observed in human neutrophils pretreated with a leukotriene B4 receptor but not a cysteinyl-leukotriene receptor antagonist. While leukotriene B4 reconstituted defective phagocytosis in leukotriene-deficient neutrophils and enhanced phagocytosis in neutrophils capable of leukotriene synthesis, leukotriene C4, leukotriene D4, 5-hydroperoxyeicosatetraenoic acid, and 5-oxo-eicosatetraenoic acid were ineffective. To determine the opsonin dependence of the leukotriene B4 augmentation of phagocytosis, we assessed the ability of leukotriene B4 to modulate neutrophil phagocytosis and the adherence of sheep erythrocytes opsonized with immunoglobulin G or the complement fragment C3bi. While leukotriene B4 augmented both Fc receptor- and complement receptor-mediated phagocytosis, increased adherence to leukotriene B4-treated neutrophils was limited to complement opsonized targets. In conclusion, we have identified a novel role for leukotriene B4 in the augmentation of neutrophil phagocytosis mediated by either the Fc or complement receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11254552      PMCID: PMC98124          DOI: 10.1128/IAI.69.4.2011-2016.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  A functional comparison of IIIindium-labelled elicited peripheral blood neutrophils and peritoneal neutrophils in the rat.

Authors:  J A Savige; S H Saverymuttu; A J Pinching
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

3.  Neutrophil chemotactic factors in bacterial pneumonia.

Authors:  H Hopkins; T Stull; S G Von Essen; R A Robbins; S I Rennard
Journal:  Chest       Date:  1989-05       Impact factor: 9.410

4.  Superoxide production of human polymorphonuclear leukocytes stimulated by leukotriene B4.

Authors:  H Sumimoto; K Takeshige; S Minakami
Journal:  Biochim Biophys Acta       Date:  1984-04-16

5.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes.

Authors:  A W Ford-Hutchinson; M A Bray; M V Doig; M E Shipley; M J Smith
Journal:  Nature       Date:  1980-07-17       Impact factor: 49.962

6.  LY171883, 1-less than 2-hydroxy-3-propyl-4-less than 4-(1H-tetrazol-5-yl) butoxy greater than phenyl greater than ethanone, an orally active leukotriene D4 antagonist.

Authors:  J H Fleisch; L E Rinkema; K D Haisch; D Swanson-Bean; T Goodson; P P Ho; W S Marshall
Journal:  J Pharmacol Exp Ther       Date:  1985-04       Impact factor: 4.030

7.  Differences in phagocytosis and killing by alveolar macrophages from humans, rabbits, rats, and hamsters.

Authors:  B Y Nguyen; P K Peterson; H A Verbrugh; P G Quie; J R Hoidal
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

8.  Activation of nitric oxide release and oxidative metabolism by leukotrienes B4, C4, and D4 in human polymorphonuclear leukocytes.

Authors:  G Lärfars; F Lantoine; M A Devynck; J Palmblad; H Gyllenhammar
Journal:  Blood       Date:  1999-02-15       Impact factor: 22.113

9.  A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders.

Authors:  T Yokomizo; K Kato; K Terawaki; T Izumi; T Shimizu
Journal:  J Exp Med       Date:  2000-08-07       Impact factor: 14.307

10.  Tumor-promoting phorbol esters stimulate C3b and C3b' receptor-mediated phagocytosis in cultured human monocytes.

Authors:  S D Wright; S C Silverstein
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

View more
  37 in total

1.  5-Lipoxygenase-deficient mice infected with Borrelia burgdorferi develop persistent arthritis.

Authors:  Victoria A Blaho; Yan Zhang; Jennifer M Hughes-Hanks; Charles R Brown
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

2.  Monocyte chemoattractant protein 1 regulates pulmonary host defense via neutrophil recruitment during Escherichia coli infection.

Authors:  Gayathriy Balamayooran; Sanjay Batra; Theivanthiran Balamayooran; Shanshan Cai; Samithamby Jeyaseelan
Journal:  Infect Immun       Date:  2011-04-25       Impact factor: 3.441

3.  Intrapulmonary administration of leukotriene B(4) augments neutrophil accumulation and responses in the lung to Klebsiella infection in CXCL1 knockout mice.

Authors:  Sanjay Batra; Shanshan Cai; Gayathriy Balamayooran; Samithamby Jeyaseelan
Journal:  J Immunol       Date:  2012-02-29       Impact factor: 5.422

Review 4.  Eicosanoid regulation of pulmonary innate immunity post-hematopoietic stem cell transplantation.

Authors:  Megan N Ballinger; Tracy R McMillan; Bethany B Moore
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007 Jan-Feb       Impact factor: 4.291

5.  Leukotrienes enhance the bactericidal activity of alveolar macrophages against Klebsiella pneumoniae through the activation of NADPH oxidase.

Authors:  Carlos H C Serezani; David M Aronoff; Sonia Jancar; Peter Mancuso; Marc Peters-Golden
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

6.  Allergic airway inflammation decreases lung bacterial burden following acute Klebsiella pneumoniae infection in a neutrophil- and CCL8-dependent manner.

Authors:  Daniel E Dulek; Dawn C Newcomb; Kasia Goleniewska; Jaqueline Cephus; Weisong Zhou; Sara Reiss; Shinji Toki; Fei Ye; Rinat Zaynagetdinov; Taylor P Sherrill; Timothy S Blackwell; Martin L Moore; Kelli L Boyd; Jay K Kolls; R Stokes Peebles
Journal:  Infect Immun       Date:  2014-06-23       Impact factor: 3.441

7.  Redundant and Cooperative Roles for Yersinia pestis Yop Effectors in the Inhibition of Human Neutrophil Exocytic Responses Revealed by Gain-of-Function Approach.

Authors:  Amanda R Pulsifer; Aruna Vashishta; Shane A Reeves; Jennifer K Wolfe; Samantha G Palace; Megan K Proulx; Jon Goguen; Sobha R Bodduluri; Bodduluri Haribabu; Silvia M Uriarte; Matthew B Lawrenz
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

8.  Increased lethality and defective pulmonary clearance of Streptococcus pneumoniae in microsomal prostaglandin E synthase-1-knockout mice.

Authors:  Jennifer M Dolan; Jason B Weinberg; Edmund O'Brien; Anya Abashian; Megan C Procario; David M Aronoff; Leslie J Crofford; Marc Peters-Golden; Lindsay Ward; Peter Mancuso
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-04-08       Impact factor: 5.464

9.  Leukotriene B4 enhances innate immune defense against the puerperal sepsis agent Streptococcus pyogenes.

Authors:  Elyara M Soares; Katie L Mason; Lisa M Rogers; Carlos H Serezani; Lucia H Faccioli; David M Aronoff
Journal:  J Immunol       Date:  2013-01-16       Impact factor: 5.422

10.  2-Arachidonoyl-glycerol- and arachidonic acid-stimulated neutrophils release antimicrobial effectors against E. coli, S. aureus, HSV-1, and RSV.

Authors:  François Chouinard; Caroline Turcotte; Xiaochun Guan; Marie-Chantal Larose; Samuel Poirier; Line Bouchard; Véronique Provost; Louis Flamand; Nathalie Grandvaux; Nicolas Flamand
Journal:  J Leukoc Biol       Date:  2012-12-12       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.